ClinicalTrials.gg
CompletedNCT06153758Updated Oct 21, 2024

Study to Learn How Different Forms of The Study Medicine Called Danuglipron Are Taken up Into the Blood In Healthy Adults

A Phase 1 interventional study of Danuglipron in Healthy Participants and Healthy Subjects, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-21.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Sep 2024, 2 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to learn how different forms of a study medication called danuglipron are taken into the blood in healthy adults, following single dose administration.

02

Conditions studied

  • Healthy Participants
  • Healthy Subjects
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older and overtly healthy
  • (BMI) between 16-32 kg/m2; and a total body weight >50 kg (110 lb)

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of medical conditions or laboratory abnormality
  • Any condition possibly affecting drug absorption
  • Known intolerance/ to a GLP-1 R agonist
  • Use of prescription drugs, nonprescription drugs, dietary supplements or herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of danuglipron in each part of the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Part A

    Participants will receive a single oral dose of danuglipron on Day 1 of each period

    Drug: Danuglipron

  • Experimental
    Part B

    Participants will receive a single oral dose of danuglipron on Day 1 of each period

    Drug: Danuglipron

  • Experimental
    Part C

    Participants will receive a single oral dose of danuglipron on Day 1 of each period

    Drug: Danuglipron

  • Experimental
    Part D

    Participants will receive a single oral dose of danuglipron on Day 1 of each period

    Drug: Danuglipron

Interventions

  • Danuglipron oral tablets

    Also known as: PF-06882961

06

What researchers measure

Primary outcomes

  1. Parts A, C and D only: Area under the concentration-time curve from time zero extrapolated to infinite time (AUCinf), as data permit, for danuglipron in the fasted state

    Time frame: Predose to 48 hours post danuglipron administration

  2. Parts A, C and D only: Maximum observed concentration (Cmax) for danuglipron in the fasted state

    Time frame: Predose to 48 hours post danuglipron administration

  3. Parts A, C and D only: Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) for danuglipron (only if AUCinf is not reportable) in the fasted state

    Time frame: Predose to 48 hours post danuglipron administration

  4. Part B only: Dose normalized area under the concentration-time curve from time zero extrapolated to infinite time (AUCinf,dn), as data permit, for danuglipron in the fasted state

    Time frame: Predose to 48 hours post danuglipron administration

  5. Part B only: Dose normalized maximum observed concentration (Cmax,dn) for danuglipron in the fasted state

    Time frame: Predose to 48 hours post danuglipron administration

  6. Part B only: Dose normalized area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast,dn) for danuglipron (only if AUCinf,dn is not reportable) in the fasted state

    Time frame: Predose to 48 hours post danuglipron administration

Secondary outcomes

  1. All Parts: Number of Participants reporting Treatment Emergent Adverse Events

    Time frame: From baseline up to 28-35 days post last dose taken

  2. All Parts: Number of Participants reporting Clinically Significant ECG Abnormalities

    Time frame: From baseline up to 28-35 days post last dose taken

  3. All Parts: Number of Participants reporting Clinically Significant Vital Sign Abnormalities

    Time frame: From baseline up to 28-35 days post last dose taken

  4. All Parts: Number of participants reporting clinically significant clinical laboratory abnormalities

    Time frame: From baseline up to 28-35 days post last dose taken

  5. All Parts: Area under the concentration-time curve from time zero extrapolated to infinite time (AUCinf), as data permit, for danuglipron in the fed state

    Time frame: Predose to 48 hours post danuglipron administration

  6. All Parts: Maximum observed concentration (Cmax) for danuglipron in the fed state

    Time frame: Predose to 48 hours post danuglipron administration

  7. All Parts: Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) for danuglipron (only if AUCinf is not reportable) in the fed state

    Time frame: Predose to 48 hours post danuglipron administration

07

Study locations

1 site
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Sep 2024, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2023
First posted
Dec 1, 2023
StartActual
Nov 27, 2023
Primary completionActual
Sep 30, 2024
CompletionActual
Sep 30, 2024
Last update
Oct 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06153758
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 1, 2023
Start date
Nov 27, 2023
Primary completion
Sep 30, 2024
Completion
Sep 30, 2024
Last update
Oct 21, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Danuglipron

Start the discussion